tiprankstipranks
Advertisement
Advertisement

ALMS Stock Latest News

Alumis reports strong Phase 3 data for envudeucitinib
Company AnnouncementsAlumis reports strong Phase 3 data for envudeucitinib
5d ago
8K
ALMS
Alumis announces topline results from ONWARD3 long-term extension study
PremiumThe Fly
Alumis announces topline results from ONWARD3 long-term extension study
5d ago
ALMS
Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target
PremiumRatings
Alumis: Competitive Pressures and Dosing Drawbacks Support Hold Rating and Unchanged $25 Price Target
12d ago
ALMS
Alumis Shareholders Reelect Directors and Ratify Auditor
PremiumCompany Announcements
Alumis Shareholders Reelect Directors and Ratify Auditor
1M ago
8K
ALMS
Alumis Highlights TYK2 Strategy in Updated Investor Presentation
PremiumCompany Announcements
Alumis Highlights TYK2 Strategy in Updated Investor Presentation
2M ago
8K
ALMS
Alumis management to meet with Cantor
PremiumThe FlyAlumis management to meet with Cantor
2M ago
ALMS
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
Premium
TipRanks Newswire
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
2M ago
ALMS
NVCT
Alumis rises 10.3%
Premium
The Fly
Alumis rises 10.3%
2M ago
ALMS
Alumis price target raised to $40 from $38 at Chardan
PremiumThe Fly
Alumis price target raised to $40 from $38 at Chardan
3M ago
ALMS
Alumis Inc. (ALMS) Q1 Earnings Cheat Sheet
PremiumPre-Earnings
Alumis Inc. (ALMS) Q1 Earnings Cheat Sheet
3M ago
ALMS
Alumis price target raised to $39 from $38 at Morgan Stanley
PremiumThe Fly
Alumis price target raised to $39 from $38 at Morgan Stanley
3M ago
ALMS
Alumis price target raised to $51 from $49 at Wells Fargo
PremiumThe Fly
Alumis price target raised to $51 from $49 at Wells Fargo
3M ago
ALMS
Alumis price target raised to $34 from $32 at Guggenheim
PremiumThe FlyAlumis price target raised to $34 from $32 at Guggenheim
3M ago
ALMS
Alumis downgraded to Neutral from Buy at H.C. Wainwright
Premium
The Fly
Alumis downgraded to Neutral from Buy at H.C. Wainwright
3M ago
ALMS
Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year
Premium
The Fly
Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year
3M ago
ALMS
Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target
PremiumRatings
Compelling Efficacy and Safety of Alumis’s Oral TYK2 Candidate Envu Underpins Buy Rating and $25 Target
4M ago
ALMS
Alumis falls -16.1%
PremiumThe Fly
Alumis falls -16.1%
5M ago
ALMS
Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
PremiumRatings
Envu’s Compelling Efficacy and Superior Safety Profile Support Buy Rating on ALMS
5M ago
ALMS
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
PremiumThe Fly
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
5M ago
JNJ
TAK
Alumis price target raised to $55 from $50 at Oppenheimer
PremiumThe FlyAlumis price target raised to $55 from $50 at Oppenheimer
5M ago
JNJ
TAK
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib
Premium
Company Announcements
Alumis Highlights Strong Phase 3 Psoriasis Results for Envudeucitinib
5M ago
8K
ALMS
Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
Premium
Ratings
Alumis Inc. (ALMS): Buy Rating on Envu’s Strong Phase 3 Data and Attractive Risk‑Reward Ahead of 2026 FDA Submission
5M ago
ALMS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >